Alnylam, Inceptive sign up to $2 billion AI drug discovery deal
Published on 06/03/2026 at 11:02 pm BST
Reuters
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 298.76 USD | -4.49% |
|
-4.48% | -24.87% |
| 07-09 | Raymond James Adjusts Price Target on Alnylam Pharmaceuticals to $468 From $420, Maintains Outperform Rating | MT |
| 07-09 | AstraZeneca's Wainua fails key heart disease trial, shares tumble | RE |
Employees
2,500
Sector
Pharmaceuticals
Trader
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
AA
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
298.76USD
Average target price
440.75USD
Spread / Average Target
+47.53%
Quarterly revenue - Rate of surprise
- Stock Market
- Stock Market News
- Alnylam, Inceptive sign up to $2 billion AI drug discovery deal
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
